Limitations of pharmacogenomic predictor discovery in Phase II clinical trials

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1443-1448

  Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Novel trial design; Pharmacogenomic response markers; Phase II studies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; TRASTUZUMAB;

BREAST CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONFOUNDING VARIABLE; DNA MICROARRAY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PREDICTION; PROTEIN ANALYSIS; SAMPLE SIZE; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO;

CLINICAL TRIALS, PHASE II AS TOPIC; DRUG THERAPY; GENETIC MARKERS; HUMANS; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS;

EID: 36448979900     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1443     Document Type: Conference Paper

References (22)

1. Chang JC, Wooten EC, Tsimelzon A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
2. Ayers M, Symmans WF, Stec J et al.: Gene-expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22, 2284-2293 (2004).
3. Iwao-Koizumi K, Matoba R, Ueno N et al.: Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol.. 23, 422-431 (2005).
4. Hannemenn J, Oosterkamp HM. Bosch CA et al.: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 23, 3331-3342 (2005).
5. Gianni L, Zambetti M, Clark K et al.: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265-727 (2005).
6. Folgueira MA, Carraro DM, Brentani H et al.: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 11, 7434-7443 (2005).
7. Dressman HK, Hans C, Bild A et al.: Gene-expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12, 819-826 (2006).
8. Thuerigen O. Schneeweiss A, Toedt G et al.: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docecaxel in primary breast cancer. J. Clin. Oncol. 24, 1839-1845 (2006).
9. Park S, Shimizu C, Shimoyama T et al.: Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 99, 9-17 (2006).
10. Cleator S, Tsimelzon A, Ashworth A et al.: Gene expression patterns for doxorubicin and cyclophosphamide, (AC) response and resistance. Breast Cancer Res. Treat. 95, 229-233 (2006).
11. Hess KR, Anderson K, Symmans WF et al.: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin. and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006).
12. Mina L, Soule SE, Badve S et al.: Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Beast Cancer Res, Treat, 103(2), 197-208 (2007).
13. Simon R: Roadmap, for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23, 7332-7341 (2005).
14. Pusztai L, Ayers M, Stec J et al.: Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin. Cancer Res. 9, 2406-2415 (2003).
15. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
16. Sotiriou C, Wirapati P, Loi S et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006).
17. Anderson K, Hess KR, Kapoor M et al.: Reproducibility of gene expression signature based predictions in replicate experiments. Clin. Cancer Res. 12, 1721-1727 (2006).
18. Wolff AC, Hammond EH, Schwartz JN et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
19. Gong Y, Yan K, Lin F et al.: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 8, 203-211 (2007).
20. Pusztai L, Anderson K, Hess KR: Pharmacogenomic predictor discovery in Phase II clinical trials for breast cancer; limitations and an alternative trial design to assess predictive markers. Clin. Cancer Res. (2007) (In Press).
21. Huang F, Reeves K, Han X et al.: Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67, 2226-2238 (2007).
22. Simon R: Clinical trials in cancer. In: Cancer Principals and Practice of Oncology (6th Edition). DeVita VT, Hellman S, Rosenberg SA (Eds),. Lippincott Williams Wilkins, PA, USA. 521-538 (2001).